Australis Capital Inc. (AUSAF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAustralis Capital Inc. (AUSAF) trades at $0.00001. Australis Capital Inc. is a cannabis company involved in cannabis and horticulture projects across multiple countries. The company's financials show negative profitability and operates in the OTC market. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for AUSAF: AUSAF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AUSAF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
AUSAF: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Australis Capital Inc. (AUSAF) Healthcare & Pipeline Overview
Australis Capital Inc., operating in the healthcare sector as a cannabis company, focuses on cannabis and horticulture projects across various international markets. With a negative profit margin of -661.5% and trading on the OTC market, the company faces unique challenges and opportunities within the evolving cannabis industry landscape.
What Is the Investment Thesis for AUSAF?
Australis Capital Inc. presents a high-risk, high-reward investment profile due to its participation in the volatile cannabis industry and its OTC market listing. The company's negative profit margin of -661.5% indicates significant challenges in achieving profitability. Key value drivers include successful expansion into new international markets and the development of innovative cannabis products. Growth catalysts involve favorable regulatory changes and increasing consumer acceptance of cannabis. Potential risks include intense competition, regulatory hurdles, and the company's ability to secure adequate funding. Investors should carefully consider the company's financial performance, market position, and the inherent uncertainties of the cannabis industry before making investment decisions. The company's beta of -0.40 suggests a low correlation with the broader market.
Based on FMP financials and quantitative analysis
AUSAF Key Highlights
Market Cap of $0.00B indicates a small company size and potential for high growth but also higher risk.
- P/E Ratio of -0.00 reflects the company's current lack of profitability.
- Profit Margin of -661.5% signals significant operational challenges and potential financial instability.
- Gross Margin of 52.4% suggests the company can generate revenue efficiently but struggles with overhead.
- Beta of -0.40 indicates a low correlation with the market, potentially offering diversification benefits.
Who Are AUSAF's Competitors?
AUSAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MKKGY Merck KGaA | $30.59 | +0.33% | $66.5B | 499-signal |
| TAK Takeda Pharmaceutical Company Limited | $18.11 | -0.55% | $57.6B | 635-pillar |
| TEVA Teva Pharmaceutical Industries Limited | $36.65 | +0.84% | $42.7B | 605-pillar |
| HLN Haleon plc | $9.22 | -0.11% | $40.6B | 775-pillar |
| SDZNY Sandoz Group AG | $81.08 | -2.68% | $35.1B | 519-signal |
| ZTS Zoetis Inc. | $72.89 | -0.57% | $30.6B | 855-pillar |
| SGIOY Shionogi & Co., Ltd. | $9.04 | +0.22% | $15.4B | 619-signal |
| ELAN Elanco Animal Health Incorporated | $22.86 | -2.93% | $11.4B | 335-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are AUSAF's Key Strengths?
Diversified operations across multiple international markets.
- Expertise in cannabis cultivation and processing.
- Potential for high growth in the expanding cannabis industry.
- Strategic focus on both medicinal and recreational cannabis markets.
What Are AUSAF's Weaknesses?
Negative profit margin indicates financial instability.
- Reliance on the volatile cannabis industry.
- Exposure to complex and evolving regulatory environment.
- Limited brand recognition compared to larger competitors.
What Could Drive AUSAF Stock Higher?
Potential changes in cannabis regulations in key markets could create new opportunities for expansion.
- Increasing consumer acceptance of cannabis for medicinal and recreational use is driving demand.
- Development and launch of innovative cannabis-based products could attract new customers.
- Strategic partnerships and acquisitions can expand the company's market reach and product portfolio.
What Are the Key Risks for AUSAF?
Intense competition from established cannabis companies could erode market share.
- Regulatory hurdles and changing legal frameworks could disrupt operations.
- Fluctuations in cannabis prices and demand could impact revenue.
- Negative profit margin indicates financial instability and potential for bankruptcy.
- OTC market listing carries higher risks due to limited information and liquidity.
What Are the Growth Opportunities for AUSAF?
- Expansion into New Geographic Markets: Australis Capital's strategy of operating in multiple international markets presents a significant growth opportunity. By successfully entering and establishing a presence in new regions, such as emerging markets in Asia or Latin America, the company can diversify its revenue streams and reduce its reliance on any single market. The global cannabis market is projected to reach $90.4 billion by 2026, offering ample opportunities for expansion.
- Development of Innovative Cannabis Products: Investing in research and development to create novel cannabis-based products can drive growth. This includes developing new formulations, delivery methods, and applications for cannabis in areas such as wellness, pharmaceuticals, and consumer goods. The market for cannabis-infused products is expected to grow rapidly, with consumers seeking innovative and convenient options.
- Strategic Partnerships and Acquisitions: Forming strategic alliances with established players in the cannabis industry or acquiring complementary businesses can accelerate growth. Partnerships can provide access to new markets, technologies, and distribution channels, while acquisitions can expand the company's product portfolio and market share. The cannabis industry is consolidating, with companies seeking to gain scale and competitive advantages through strategic transactions.
- Focus on Medical Cannabis Applications: The medical cannabis market offers significant growth potential, driven by increasing acceptance of cannabis as a treatment for various medical conditions. Australis Capital can focus on developing cannabis-based therapies for specific ailments, such as pain management, anxiety, and epilepsy. The medical cannabis market is expected to grow as more research supports the therapeutic benefits of cannabis.
- Enhancing Operational Efficiency and Cost Management: Improving operational efficiency and reducing costs can enhance profitability and drive growth. This includes optimizing cultivation practices, streamlining supply chain management, and implementing cost-control measures across the organization. By improving its financial performance, Australis Capital can attract investors and secure funding for future growth initiatives.
What Are AUSAF's Competitive Advantages?
- Established presence in multiple international markets.
- Expertise in cannabis cultivation and processing.
- Proprietary cannabis-based product formulations.
- Strategic partnerships with key players in the cannabis industry.
What Does AUSAF Do?
Australis Capital Inc., based in Las Vegas, Nevada, is a cannabis company engaged in cannabis and horticulture projects across a diverse range of international markets. These markets include the United States, Canada, Denmark, Finland, Iceland, Germany, the Netherlands, Bahrain, the United Arab Emirates, Southeast Asia, and Australia. The company's business model focuses on identifying and developing opportunities within the cannabis industry, spanning cultivation, processing, and distribution. While the company's specific founding story is not detailed in the provided data, its current operations reflect a strategic approach to establishing a global footprint in the burgeoning cannabis market. Australis Capital aims to capitalize on the increasing legalization and acceptance of cannabis for both medicinal and recreational purposes. The company's activities encompass various aspects of the cannabis value chain, from cultivation and product development to branding and retail strategies. Australis Capital navigates a complex regulatory environment, adapting its strategies to comply with local laws and regulations in each jurisdiction where it operates. The company seeks to differentiate itself through innovative product offerings and strategic partnerships.
What Products and Services Does AUSAF Offer?
- Cultivates cannabis plants in various locations.
- Processes cannabis into different forms, such as oils and edibles.
- Distributes cannabis products to retailers and consumers.
- Develops and markets cannabis-based products.
- Operates in multiple international markets, including the US, Canada, and Europe.
- Engages in horticulture projects related to cannabis cultivation.
- Navigates the complex regulatory environment of the cannabis industry.
How Does AUSAF Make Money?
- Generates revenue through the sale of cannabis products.
- Focuses on both medicinal and recreational cannabis markets.
- Expands operations through strategic partnerships and acquisitions.
What Industry Does AUSAF Operate In?
Australis Capital Inc. operates within the rapidly evolving cannabis industry, characterized by increasing legalization, growing consumer demand, and intense competition. The industry faces regulatory complexities, varying legal frameworks across jurisdictions, and challenges in establishing consistent quality standards. Australis Capital competes with other cannabis companies, including AYRWF (Ayr Wellness Inc.), BUDZ (BUDZ), CBIH (Clever Leaves International Inc.), DHBUF (Dutch Harvest B.V.), and FAGI (First American Green, Inc.), each vying for market share and brand recognition.
Who Are AUSAF's Key Customers?
- Retail consumers seeking cannabis products for recreational use.
- Patients using medical cannabis for therapeutic purposes.
- Retail dispensaries and stores selling cannabis products.
- Wholesale distributors of cannabis products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 59 |
| 2026-08-26 | 59 |
| 2026-08-29 | 59 |
| 2026-09-01 | 59 |
| 2026-09-04 | 59 |
| 2026-09-07 | 59 |
| 2026-09-10 | 59 |
What changed?
The score has stayed at 59.
Over the same 18 days the stock moved +0.0%.
Company Profile
Australis Capital Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Terrance R. Booth. AUSAF has traded publicly since 2018.
Key Financial Metrics
Return on assets is -99.0%, showing how much profit it generates from its asset base. A current ratio of 0.69 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Australis Capital Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
AUSAF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diversified operations across multiple international markets.
- Expertise in cannabis cultivation and processing.
- Potential for high growth in the expanding cannabis industry.
- Strategic focus on both medicinal and recreational cannabis markets.
Bear Case
- Negative profit margin indicates financial instability.
- Reliance on the volatile cannabis industry.
- Exposure to complex and evolving regulatory environment.
- Limited brand recognition compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
AUSAF Latest News
-
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
benzinga · Dec 18, 2025
-
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
benzinga · Dec 17, 2025
-
Hess Midstream Signs $100M Repurchase That Includes Class B Units Of Hess Midstream Operations From chevron Affiliate And Hess Midstream's Class A Shares From Public
benzinga · Aug 5, 2025
-
Marijuana Stock Movers For July 7, 2025
benzinga · Jul 7, 2025
AUSAF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AUSAF.
Price Targets
Wall Street price target analysis for AUSAF.
AUSAF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AUSAF; grades run from A+ (80-100) to F (below 30).
Latest News
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
Hess Midstream Signs $100M Repurchase That Includes Class B Units Of Hess Midstream Operations From chevron Affiliate And Hess Midstream's Class A Shares From Public
Marijuana Stock Movers For July 7, 2025
Leadership: Terrance R. Booth
CEO
Terrance R. Booth serves as the CEO of Australis Capital Inc. His background likely includes experience in business management, strategic planning, and the cannabis industry. His role involves overseeing the company's operations, developing and implementing strategic initiatives, and ensuring compliance with regulatory requirements.
Track Record: Terrance R. Booth's track record at Australis Capital Inc. is not detailed in the provided data. However, as CEO, he is responsible for the company's overall performance and strategic direction. Key achievements and milestones under his leadership would include successful expansion into new markets, the development of innovative cannabis products, and improvements in financial performance. His decisions and actions would significantly impact the company's ability to navigate the challenges and capitalize on the opportunities in the cannabis industry.
AUSAF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Australis Capital Inc. may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as those listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for limited information availability, price volatility, and liquidity constraints. This tier is often populated by companies that are early-stage, distressed, or have chosen not to meet the listing requirements of higher exchanges.
- OTC Tier: OTC Other
- Limited information availability due to lower disclosure requirements.
- Higher price volatility due to thin trading volume.
- Potential for fraud or manipulation due to less regulatory oversight.
- Liquidity constraints may make it difficult to buy or sell shares.
- Increased risk of delisting or going out of business.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Monitor the company's news and press releases for any red flags.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation for several years.
- The company has a website and publishes press releases.
- The company has a management team with relevant experience.
- The company operates in a regulated industry (cannabis).
- The company has a clear business model and revenue streams.
Common Questions About AUSAF (Healthcare)
Is AUSAF a good stock?
Stock Expert AI does not rate AUSAF buy, sell or hold. Australis Capital Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does Australis Capital Inc. do?
Australis Capital Inc. operates as a cannabis company with a focus on cannabis and horticulture projects across various international markets.
What are the key factors to evaluate for AUSAF?
Evaluate AUSAF on fundamentals, analyst consensus, and risk factors. Australis Capital Inc. presents a high-risk, high-reward investment profile due to its participation in the volatile cannabis industry and its OTC market listing. Not financial advice.
How frequently does AUSAF data refresh on this page?
AUSAF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AUSAF's recent stock price performance?
Australis Capital Inc. (AUSAF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified operations across multiple international markets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AUSAF overvalued or undervalued right now?
Australis Capital Inc. (AUSAF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of AUSAF?
Yes, most major brokerages offer fractional shares of Australis Capital Inc. (AUSAF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track AUSAF's earnings and financial reports?
Australis Capital Inc. (AUSAF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for AUSAF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.